Farkas A, Leprán I, Papp J G
Department of Pharmacology, Albert Szent-Györgyi Medical University, Szeged, Hungary.
Acta Physiol Hung. 1996;84(3):281-2.
The antiarrhythmic effect of almokalant, a new type III antiarrhythmic agent, was examined by occluding and releasing the left circumflex coronary artery for 10 min, respectively, in openchest, pentobarbital-anaesthetized albino rabbits. Almokalant pretreatment increased the number of animals developing no arrythmias (5/9 vs. 1/12 in controls), and decreased the incidence of ventricular fibrillation (1/9 vs. 9/12) during reperfusion. According to our results almokalant can protect the heart against arrhythmias induced by ischaemia and reperfusion.
在戊巴比妥麻醉的开胸白化兔中，通过分别阻断和再通左旋冠状动脉10分钟，研究了新型III类抗心律失常药物阿尔莫卡兰的抗心律失常作用。阿尔莫卡兰预处理增加了未发生心律失常动物的数量（5/9 vs. 对照组1/12），并降低了再灌注期间室颤的发生率（1/9 vs. 9/12）。根据我们的结果，阿尔莫卡兰可保护心脏免受缺血和再灌注诱导的心律失常的影响。
